BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, Sokol EV, Torgashina AV, Vinogradova IB, Abdulganieva DI, Zimenko AY. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Naučno-praktičeskaâ revmatologiâ 2021;59:666-675. [DOI: 10.47360/1995-4484-2021-666-675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Krichevskaya OA, Dubinina TV, Ilinykh EV, Demina AB, Andrianova IA. COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth. Naučno-praktičeskaâ revmatologiâ 2022;60:413-419. [DOI: 10.47360/1995-4484-2022-413-419] [Reference Citation Analysis]
2 Baimukhamedov CT, Botabekova AK, Dossybayeva GN, Makhmudov SA. Rheumatoid arthritis and post-COVID-19 syndrome. Naučno-praktičeskaâ revmatologiâ 2022;60:276-279. [DOI: 10.47360/1995-4484-2022-276-279] [Reference Citation Analysis]
3 Erdes SF. Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis. Naučno-praktičeskaâ revmatologiâ 2022;60:267-270. [DOI: 10.47360/1995-4484-2022-267-270] [Reference Citation Analysis]
4 Baimukhamedov CT, Botabekova AK, Dossybayeva GN, Makhmudov SA. Rheumatoid arthritis and post-COVID-19 syndrome. Naučno-praktičeskaâ revmatologiâ 2022;60:276-279. [DOI: 10.47360/1995-4484-2022-276-279] [Reference Citation Analysis]
5 Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv 2022;94:605-609. [DOI: 10.26442/00403660.2022.05.201501] [Reference Citation Analysis]
6 Karateev AE, Polishchuk EY, Potapova AS, Matyanova EV, Semashko AS, Bobkova АO, Filatova ES, Amirjanova VN, Glukhova SI, Zotkin EG, Lila AM. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients. Naučno-praktičeskaâ revmatologiâ 2022;60:149-156. [DOI: 10.47360/1995-4484-2022-149-156] [Reference Citation Analysis]
7 Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Aronova ES, Belov BS, Gridneva GI. Post covid syndrome and rheumatic diseases: focus on rheumatoid arthritis (own data). Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-2-108-113] [Reference Citation Analysis]
9 Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Naučno-praktičeskaâ revmatologiâ 2022;60:5-20. [DOI: 10.47360/1995-4484-2022-5-20] [Reference Citation Analysis]
10 Lila AM, Chuchalin AG, Torshin IY, Gromova OA. Important aspects of osteoarthritis therapy during the COVID-19 pandemic. Sovremennaâ revmatologiâ 2022;16:108-114. [DOI: 10.14412/1996-7012-2022-1-108-114] [Reference Citation Analysis]